The pyrrole moiety as a template for COX-1/COX-2 inhibitors

被引:185
作者
Dannhardt, G
Kiefer, W
Krämer, G
Maehrlein, S
Nowe, U
Fiebich, B
机构
[1] Johannes Gutenberg Univ Mainz, Inst Pharm, D-55099 Mainz, Germany
[2] Hoffmann La Roche Ag, Dept Pharmaceut Technol, D-79630 Grenzach Wyhlen, Germany
[3] Hosp Albert Ludwigs Univ Freiburg, Dept Psychiat & Psychotherapy, D-79104 Freiburg, Germany
关键词
COX-1/COX-2; inhibition; pyrrole derivatives; enzyme selectivity; structure-activity relationship;
D O I
10.1016/S0223-5234(00)00150-1
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aroyl- and thiophene-substituted pyrrole derivatives have been synthesized as a new class of COX-1/COX-2 inhibitors. The inhibition of COX-1 was evaluated in a biological system using bovine PMNLs as the enzyme source, whereas LPS-stimulated human monocytes served as the enzyme source for inducible COX-2. The determination of the concentration of arachidonic acid metabolites was performed by HPLC for COX-1 and RIA for COX-2. Variation of the substitution pattern led to a series of active compounds which showed inhibition for COX-1 and COX-2. Structural requirements for the development of COX-1/COX-2 inhibitors are discussed, (C) 2000 Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:499 / 510
页数:12
相关论文
共 55 条
  • [1] Alberola A., 1990, J CHEM SOC P1, V10, P2681
  • [2] ANTIFUNGAL AGENTS .9. 3-ARYL-4-[ALPHA-(1H-IMIDAZOL-1-YL)ARYLMETHYL]PYRROLES - A NEW CLASS OF POTENT ANTICANDIDA AGENTS
    ARTICO, M
    DISANTO, R
    COSTI, R
    MASSA, S
    RETICO, A
    ARTICO, M
    APUZZO, G
    SIMONETTI, G
    STRIPPOLI, V
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (21) : 4223 - 4233
  • [3] Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
    Beiche, F
    Scheuerer, S
    Brune, K
    Geisslinger, G
    GoppeltStruebe, M
    [J]. FEBS LETTERS, 1996, 390 (02): : 165 - 169
  • [4] From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors
    Black, WC
    Bayly, C
    Belley, M
    Chan, CC
    Charleson, S
    Denis, D
    Gauthier, JY
    Gordon, R
    Guay, D
    Kargman, S
    Lau, CK
    Leblanc, Y
    Mancini, J
    Ouellet, M
    Percival, D
    Roy, P
    Skorey, K
    Tagari, P
    Vickers, P
    Wong, E
    Xu, L
    Prasit, P
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1996, 6 (06) : 725 - 730
  • [5] TOLMETIN - REVIEW OF ITS PHARMACOLOGICAL PROPERTIES AND THERAPEUTIC EFFICACY IN RHEUMATIC DISEASES
    BROGDEN, RN
    HEEL, RC
    SPEIGHT, TM
    AVERY, GS
    [J]. DRUGS, 1978, 15 (06) : 429 - 450
  • [6] KETOROLAC - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL
    BUCKLEY, MMT
    BROGDEN, RN
    [J]. DRUGS, 1990, 39 (01) : 86 - 109
  • [7] INVITRO EVALUATION OF 5-LIPOXYGENASE AND CYCLOOXYGENASE INHIBITORS USING BOVINE NEUTROPHILS AND PLATELETS AND HPLC
    DANNHARDT, G
    LEHR, M
    [J]. JOURNAL OF PHARMACY AND PHARMACOLOGY, 1992, 44 (05) : 419 - 424
  • [8] DANNHARDT G, IN PRESS CURR PHARM
  • [9] Cytotoxic activities of Mannich bases of chalcones and related compounds
    Dimmock, JR
    Kandepu, NM
    Hetherington, M
    Quail, JW
    Pugazhenthi, U
    Sudom, AM
    Chamankhah, M
    Rose, P
    Pass, E
    Allen, TM
    Halleran, S
    Szydlowski, J
    Mutus, B
    Tannous, M
    Manavathu, EK
    Myers, TG
    De Clercq, E
    Balzarini, J
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (07) : 1014 - 1026
  • [10] DISANTO R, 1993, FARMACO, V48, P209